Invivyd Inc. Common Stock (IVVD)

FairStock Score: 62/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits, generate cash, and possess durable competitive advantages. Invivyd fails the first test. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $14.3 million while net income was -$44.4 million, a -310.77% margin. That loss ballooned from -$14.7 million in fiscal Q2 2025. Full-year fiscal 2025 revenue was $53.4 million and net loss -$52.5 million, an improvement from fiscal 2024's $25.4 million revenue and -$169.9 million loss, but the latest quarters show losses widening again: -$41.4 million in fiscal Q1 2026 and -$44.4 million in fiscal Q2 2026. Trailing free cash flow is -$109.7 million, a -57.6% FCF yield on a $190.4 million market cap. The Piotroski F-Score is 2/9 and the Altman Z-Score is -3.43, warning of financial weakness. The debt-to-equity ratio of 0.05 is low, so debt is not the main problem; cash burn is. At $0.65, P/B is 1.06 and P/E is -2.08—there are no earnings to value. A monoclonal antibody business like PEMGARDA may help people, but it faces viral evolution, competition, and reimbursement risk. Without a durable moat or self-sustaining cash flow, this is speculation, not a Graham margin-of-safety bargain. I would require evidence of a path to profitability and a much stronger balance sheet before calling it cheap.

In plain English: Invivyd makes antibody therapies for viral infections, including a COVID-19 prevention product. The business is growing revenue but is still losing a lot of money and burning cash, with losses getting bigger in recent quarters. At $0.65, the price looks low compared with its past high, but because the company has no profits and weak financial scores, it does not look clearly cheap on business fundamentals.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer